Contents

Search


DCVax-L; autologous dendritic cell vaccine

Indications: - glioblastoma, adjunct to standard therapy Adverse effects: - similar to standard therapy

General

vaccine Immunotherapy

References

  1. Liau LM, Ashkan K, Tran DD et al First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 2018. 16:142 PMID: 29843811 Free PMC Article https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6